Gastrointestinal Cancer

Positioning 177-Lu-Dotatate Therapy and 68-Ga-Dotatate Scans in Management of Neuroendocrine Tumors

Caroline Helwick  / September 10, 2017

The results of the phase III NETTER-1 trial, recently published in The New England Journal of Medicine,1 have been met with great interest by clinicians who treat neuroendocrine tumors. In patients with advanced midgut lesions, treatment with the radiopharmaceutical lutetium-177-Dotatate (177-Lu-Dot...

Global Cancer Care

First Comprehensive Pediatric Hematology/Oncology Initiative Launched in Africa

The ASCO Post  / July 10, 2017

Through public-private partnerships with the governments of Botswana, Uganda, and Malawi, His Excellency the President Lieutenant General Dr. Seretse Khama Ian Khama, of the Republic of Botswana; the Honorable Minister Dorcas Makgato, of the Ministry of Health and Wellness; the Bristol-Myers Squibb ...

Lung Cancer

The Ongoing Challenges of Lung Cancer Screening

Ronald Piana  / May 25, 2017

Lung cancer persistently remains the leading cause of cancer death among men and women in the United States. Only about 15% of lung cancers are diagnosed at the localized stage, when clinical intervention could markedly improve patient outcomes. For decades, lung cancer specialists and advocacy grou...

Pancreatic Cancer

ESTRO 2017: Study Suggests Role for Radiotherapy in Extending Survival in Patients With Early-Stage Pancreatic Cancer

The ASCO Post  / May 25, 2017  / 43537

Radiotherapy at a high enough dose may increase survival in early-stage pancreatic cancer, according to research presented at the European Society for Radiotherapy & Oncology (ESTRO) 36 Conference.1 Previous research has suggested that radiotherapy may be of little help in this setting. The stu...

Issues in Oncology

Tackling the Obesity and Cancer Epidemic

Jo Cavallo  / May 25, 2017

The above illustration depicts the labyrinth of etiologic pathways that may be involved in triggering the metabolic mechanisms leading to obesity-related cancers. (See “Understanding the Biologic Triggers” below.) Illustration by Adam Questell © 2017 Research is still ...

Bladder Cancer

SWOG Launches First Prospective Registration Trial With Atezolizumab in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer

Parminder Singh, MD  / May 10, 2017

Peter Black, MD, FRCSC, FACS Study Co-Chair Parminder Singh, MD Study Co-Chair Seth P. Lerner, MD, FACS Senior Study Chair Rick Bangs Patient Advocate The standard of care for patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle inva...

Issues in Oncology
Health-Care Policy

Accelerating Pediatric Drug Development: Master Protocols May Be a Way to Go

Margot J. Fromer  / April 25, 2017

Pediatric drug development should be coordinated with that for adults as part of an overall program. — Gregory Reaman, MD Development of pediatric cancer drugs has long lagged behind adult drug development for two major reasons: The process is more difficult, and childhoo...

Issues in Oncology

Scientists Tackle Next Set of Immunotherapy Challenges

Caroline Helwick  / March 10, 2017

Cancer immunotherapy is about to get much more complicated. Just as oncologists are becoming familiar with checkpoint inhibitors and their growing indications, they will eventually be challenged with using them in novel combinations and in new tumor types. This will be the fruit that comes from unde...

Head and Neck Cancer

Novel Immunotherapy Added to Standard Care Did Not Meet Endpoint in Patients With Advanced Head and Neck Cancer

Caroline Helwick  / March 10, 2017  / 35862

While the addition of motolimod to the EXTREME regimen did not improve progression-free or overall survival in first-line recurrent or metastatic squamous cell carcinoma of the head and neck, post hoc analysis suggests that subjects with injection-site reactions benefited from the ...

Head and Neck Cancer

Expert Point of View: Cornelius J.M. Melief, MD, PhD

Caroline Helwick  / March 10, 2017

Conceivably, motolimod can affect certain leukocyte subsets, such as myeloid-derived suppressor cells, but also positively affect other leukocyte populations, such as macrophages, dendritic cells, and natural killer cells. — Cornelius J.M. Melief, MD, PhD Cornelius J.M. M...

Cost of Care

Value-Based Approaches to the Rising Costs of Cancer Drugs

Alice Goodman  / March 10, 2017  / 36751

The U.S. is underperforming [in matters of drug value] compared with other developed countries. For both branded and generic drugs, we spend more per patient than many other countries, even though all patients don’t have access to these drugs. — Peter B. Bach, MD, MAPP It...

Multiple Myeloma

CAR T-Cell Therapy Emerging in Multiple Myeloma

Caroline Helwick  / March 10, 2017  / 36569

For patients with multiple myeloma, chimeric antigen receptor (CAR) T-cell therapy is gaining ground in pilot studies. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, researchers presented their latest findings for this innovative therapy, which has proven beneficia...

Multiple Myeloma

Expert Point of View: Edward A. Stadtmauer, MD

Caroline Helwick  / March 10, 2017

The age of cellular immunotherapy for myeloma is upon us. — Edward A. Stadtmauer, MD In a lecture at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, Edward A. Stadtmauer, MD, Chief of the Hematologic Malignancies Section at the University of...

ASCO and NCCN to Collaborate on Guidelines on Management of Immunotherapy Side Effects

The ASCO Post  / March 10, 2017

ASCO and the National Comprehensive Cancer Network® (NCCN®) have announced a joint collaboration to publish practical clinical guidance on the management of side effects caused by immunotherapy. This novel collaboration aims to rapidly support improved quality of care for the growing number of patie...

Hematologic Malignancies

Pacritinib Reduces Spleen Volume in Myelofibrosis

Alice Goodman  / March 10, 2017

The investigational drug pacritinib met the primary endpoint of the phase III PERSIST-2 trial in high-risk patients with myelofibrosis and thrombocytopenia. Treatment with the Janus kinase (JAK)1/2 inhibitor pacritinib achieved a significant reduction in spleen volume compared with best available th...

Expert Point of View: Selina Luger, MD, Stephanie Lee, MD, and Gabriela Hobbs, MD

Alice Goodman  / March 10, 2017

Selina Luger, MD Speaking at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, before the hold on pacritinib was lifted (in January 2017), Selina Luger, MD, of the University of Pennsylvania, Philadelphia, commented, “I think the U.S. Food and Drug Administratio...


Phase II Studies Evaluate New Approaches in Richter Transformation

Caroline Helwick  / February 25, 2017

Despite advances in treating chronic lymphocytic leukemia (CLL), the 5% to 10% of patients who develop Richter transformation continue to have poor outcomes. For these patients, median progression-free survival is approximately 6 months, and median overall survival is about 8 months. Phase II studie...

Expert Point of View: Jose Leis, MD, PhD

Caroline Helwick  / February 25, 2017

Jose Leis, MD, PhD Jose Leis, MD, PhD, of the Mayo Clinic in Arizona, commented on the promise of checkpoint inhibitors in Richter transformation. “At Mayo, we have treated more than 30 patients with programmed cell death protein 1 (PD-1) blockade. We do see that chronic lymphocytic leukemi...

Prostate Cancer

On the Horizon: New Tools for Prostate Cancer

Alice Goodman  / February 10, 2017

Prostate-specific membrane antigen scan has the ability to revolutionize the way we treat prostate cancer. — William Dahut, MD The field of prostate cancer is being energized by discoveries in genetics, novel imaging techniques, and the potential of checkpoint inhibitors ...

City of Hope, Translational Genomics Research Institute Combine to Advance Precision Medicine and Speed Translational Research

The ASCO Post  / December 10, 2016

City of Hope and Translational Genomics Research Institute (TGen) have announced an alliance to make precision medicine a reality for patients. This alliance enables both institutes to complement each other in their common areas of research and patient care, with City of Hope providing a significant...

Multiple Myeloma

Genetic Link May Explain Outcomes Differences in Multiple Myeloma in African Americans

Ronald Piana  / December 10, 2016

We found several very subtle differences in tumors between the two populations [those of European vs African ancestry], but the most striking observation was the higher TP53 mutation occurrence in the patients of European ancestry. — Zarko Manojlovic, PhD African American...

Supportive Care

What’s New in Antiemesis Therapy

Caroline Helwick  / December 10, 2016

Adherence to antiemesis guidelines is not very good, especially with highly emetogenic chemotherapy. If you do adhere to the guidelines, you have better control over nausea and vomiting, but choosing wisely is using what you need—and nothing more. — Frankie Ann Holmes, MD ...

Issues in Oncology

Disparities of Care: Navigation System Helps Connect Underserved Populations to Cancer Services

Ronald Piana  / December 10, 2016

The trend of higher completion of cancer control behaviors among participants who received navigation was clear: Colorectal cancer screening increased by 40%, mammography increased by 17%, human papillomavirus vaccination of daughters increased by 43%, and participation in smoking ...

NCCN Imaging Appropriate Use Criteria Published for 15 Additional Guidelines

The ASCO Post  / December 10, 2016

The National Comprehensive Cancer Network® (NCCN®), a Centers for Medicare & Medicaid Services (CMS)-approved provider-led entity for imaging appropriate use criteria, continues to build its library of these standards and has published NCCN Imaging Appropriate Use Criteria™ for an additional 15 ...

NCCN Launches Campaign to Eradicate Fatal Vincristine Errors

Caroline McNeil  / December 10, 2016

It is uniformly fatal and impossible to undo. When the chemotherapy drug vincristine is placed in a syringe and injected intrathecally—into the spinal fluid—the patient always dies. And despite safety guidelines and labels, deaths continue to occur. Now the National Comprehensive Cancer Network® (N...

ASCO Releases Criteria for High-Quality Clinical Pathways in Oncology

The ASCO Post  / December 10, 2016

ASCO seeks to guide the future development and implementation of pathways, while addressing stakeholder concerns that have surfaced following the rapid adoption of pathways in oncology. — Daniel F. Hayes, MD, FACP, FASCO ASCO recently released its Criteria for High-Qualit...

Bladder Cancer

KEYNOTE-045 Trial Finds Pembrolizumab Improves Survival Over Chemotherapy in Advanced Urothelial Cancer

The ASCO Post  / November 10, 2016

The results of KEYNOTE-045 represent a major breakthrough and will be welcome news for patients dealing with previously treated advanced urothelial cancer. — Roger M. Perlmutter, MD, PhD The phase III KEYNOTE-045 trial, investigating the use of the anti–PD-1 (programmed c...

Advanced Practitioners Convene for Annual JADPRO Live at APSHO Meeting

The ASCO Post  / November 10, 2016  / 36326

Pamela Hallquist Viale, RN, MS, CNS, ANP Heather M. Hylton, MS, PA-C Wendy H. Vogel, MSN, FNP, AOCNP® Sandra E. Kurtin, RN, MS, AOCN®, ANP Christopher J. Campen, PharmD, BCPS, BCOP The fourth annual JADPRO Live conference was held recently in conj...

Health-Care Policy

NIH Expands National Precision Medicine Initiative Cohort Program

The ASCO Post  / October 25, 2016

The National Institutes of Health (NIH) has announced awards to add four regional medical center groups to the national network of health-care provider organizations that will implement the Precision Medicine Initiative Cohort Program. Combined, the new health-care provider organizations will receiv...

The Medicinal Power of Minerals

Jo Cavallo  / October 25, 2016

In September, the National Institutes of Health (NIH), in partnership with the Smithsonian Institution National Museum of Natural History, opened the Minerals in Medicine exhibition at the NIH Clinical Center in Bethesda, Maryland. The exhibition, which includes more than 40 minerals and meta...

Issues in Oncology

New American Cancer Society Report Reveals Gaps, Identifies Unique Barriers in Pediatric Cancer Research

The ASCO Post  / October 25, 2016

The numbers here tell a compelling story…. There are still areas of research where progress is urgently needed. — Katherine Sharpe A first-of-its-kind joint report from the American Cancer Society and the Alliance for Childhood Cancer has compiled the latest information r...

Multiple Myeloma

Multiple Myeloma Research Foundation to Donate Data to NCI’s Genomic Data Commons

The ASCO Post  / October 10, 2016

The National Cancer Institute (NCI) recently announced a collaboration with the Multiple Myeloma Research Foundation to incorporate the Foundation’s wealth of genomic and clinical data about the disease into the NCI Genomic Data Commons. NCI’s Genomic Data Commons is a publicly available database th...

Cancer Moonshot Blue Ribbon Panel Recommends 10 Ways to Speed Cancer Advances

Jo Cavallo  / September 25, 2016

Earlier this month, members of the National Cancer Moonshot Initiative’s Blue Ribbon Panel submitted an ambitious list of 10 recommendations on the scientific approaches that are most likely to accelerate progress against cancer to the President’s National Cancer Advisory Board. The panel’s suggesti...

Breast Cancer

Nipple-Sparing Mastectomy Shown to Be Safe—and Increasingly Preferred

Caroline Helwick  / September 10, 2016

In more than 500 risk-reducing nipple-sparing mastectomies in 348 deleterious BRCA-mutation carriers, we identified no cases of primary breast cancer on the side of the prophylactic procedure. — James Jakub, MD Prophylactic mastectomy that preserves a woman’s nipple is on...

Expert Point of View: Julie ­Margenthaler, MD

Caroline Helwick  / September 10, 2016

Julie ­Margenthaler, MD The moderator of the press briefing, Julie ­Margenthaler, MD, of Washington University, St. Louis, maintained there are few contraindications for nipple-sparing mastectomy. “I reiterate Dr. Jakub’s view. I agree it’s absolutely safe for BRCA-positive patients,” she d...

Epithelial Cells on the Tail Fin of Genetically Engineered Zebrafish

The ASCO Post  / August 10, 2016

Photo Credit: Chen-Hui Chen, Duke University Image depicts hundreds of live cells from a tiny bit of skin on the tail fin of a genetically engineered adult zebrafish. The cells have been labeled with a new fluorescent imaging tool called Skinbow. It uniquely color codes cells by getting them t...

Health-Care Policy

Photonics and the Cancer Moonshot Initiative: Partnership Highlights Role of Technology and IT Infrastructure in Reaching Goals

Caroline McNeil  / August 10, 2016

Photonics—the science of light—may not be associated with cancer in most people’s minds. But photonic technologies are: CT (computed tomography) scans and digital x-rays, for instance, are in everyday use, and next-generation oncology applications are in development. As the White House’s National C...

Issues in Oncology

Survey Finds Most Americans Unlikely to Enroll in Clinical Trials

The ASCO Post  / June 10, 2016

According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted for Memorial Sloan Kettering Cancer Center (MSK), only 35% of Americans indicated that they were “likely” to enroll in a clinical trial. Clinical research is increasingly dependent upon larger numbers of cance...


Seattle Children’s Reports Promising Early Results With Immunotherapy in Relapsed ALL

The ASCO Post  / June 10, 2016

Seattle Children’s announced that 39 of 42 patients treated in a phase I clinical trial using genetically reprogrammed T cells to treat relapsed or refractory acute lymphoblastic leukemia (ALL) have achieved complete remission, showing no detectable leukemia cells. Phase II of this trial, known as t...

Pancreatic Cancer

Phase Ib/II Study Reports High Response Rates Seen With Addition of Cisplatin to Regimen for Advanced Pancreatic Cancer

Caroline Helwick  / April 10, 2016

An 80% response rate with traditional chemotherapy is basically unheard of [in advanced pancreatic cancer]. But we know this is a very small sample, and we are very cautious. — Gayle Jameson, MSN, ACNP-BC, AOCN The oncology research team at HonorHealth Research Institute in Scott...